Mark Feitelson holds a Ph.D. in Microbiology/Immunology from UCLA and has conducted research on hepatitis B at Stanford University and Fox Chase Cancer Center before joining Temple University as a Professor of Biology. He serves as Chief Scientific Officer of SFA Therapeutics.
Intro paths
YC
Mark went through Y Combinator (Summer 2021) — any YC alum in your network can reach them through the YC community.
→
In turn, Mark can intro founders to SFA Therapeutics's investors below.
SFA Therapeutics's investors · 1
Co-founders
Ira Spector· FounderAlla Arzumanyan· Co-Founder & Chief Development OfficerIra C. Spector· Co-Founder & Chief Scientific Officer